Etanercept in patients with inflammatory hand osteoarthritis (EHOA): a multicentre, randomised, double-blind, placebo-controlled trial.
Margreet KloppenburgRoberta RamondaKlaus BobaczWing-Yee KwokDirk ElewautTom W J HuizingaFéline P B KroonLeonardo PunziJosef S SmolenBert Vander CruyssenRon WolterbeekGust VerbruggenRuth WittoekPublished in: Annals of the rheumatic diseases (2018)
Anti-TNF did not relieve pain effectively after 24 weeks in erosive osteoarthritis. Small subgroup analyses showed a signal for effects on subchondral bone in actively inflamed joints, but future studies to confirm this are warranted.
Keyphrases
- double blind
- rheumatoid arthritis
- placebo controlled
- phase iii
- clinical trial
- study protocol
- disease activity
- chronic pain
- knee osteoarthritis
- ankylosing spondylitis
- phase ii
- pain management
- bone mineral density
- oxidative stress
- current status
- neuropathic pain
- juvenile idiopathic arthritis
- randomized controlled trial
- rheumatoid arthritis patients
- soft tissue
- gestational age
- spinal cord
- body composition
- preterm birth